Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Neha Panjwani

Is Incyte Stock Outperforming the Dow?

Incyte Corporation (INCY), headquartered in Wilmington, Delaware, discovers, develops, and commercializes therapeutics for hematology/oncology, as well as inflammation and autoimmunity areas. Valued at $18.5 billion by market cap, the company follows the science to find solutions for patients with unmet medical needs.

Companies worth $10 billion or more are generally described as “large-cap stocks,” and INCY perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the biotechnology industry. INCY has a strong portfolio of approved products. Its diverse pipeline in oncology and dermatology demonstrates a commitment to innovation and addressing unmet medical needs, providing multiple revenue streams and reducing dependency on a single product.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.